ACAP2 Inhibitors
ACAP2 inhibitors encompass a diverse array of chemicals targeting critical cellular pathways associated with ACAP2 function. SecinH3, an ARF inhibitor, disrupts ARF GTPase activation, indirectly modulating ACAP2 by affecting ARF-mediated recruitment to cellular membranes, impacting membrane trafficking and cellular morphology. CID1067700, a PLD inhibitor, disrupts PLD activity, indirectly modulating ACAP2 by altering phospholipid metabolism, impacting processes related to membrane trafficking and vesicle formation. Brefeldin A, an ARF activation inhibitor, influences ACAP2 by affecting ARF-mediated recruitment to cellular membranes, impacting membrane trafficking and vesicle formation. Exo1, a PLD1 inhibitor, disrupts PLD1 activity, indirectly modulating ACAP2 by altering phospholipid metabolism, impacting membrane trafficking and vesicle formation. Dyngo-4a, a dynamin GTPase inhibitor, disrupts endocytosis, indirectly modulating ACAP2 by affecting dynamin-dependent vesicle trafficking, impacting endocytosis and membrane dynamics.
Soraphen A, an ACC inhibitor, disrupts lipid metabolism, indirectly influencing ACAP2 by altering lipid substrate availability, impacting membrane trafficking and vesicle formation. YM201636, a PI4KB inhibitor, disrupts phosphoinositide synthesis, indirectly modulating ACAP2 by affecting phosphoinositide availability, impacting membrane trafficking and vesicle formation. CAL-101 (Idelalisib), a PI3K inhibitor, disrupts PI3K signaling, indirectly influencing ACAP2 by altering phosphoinositide availability, impacting membrane trafficking and vesicle formation. EHT 1864 and NSC23766, Rac1 inhibitors, disrupt Rac1 activation, indirectly modulating ACAP2 by affecting downstream events, impacting cellular migration and membrane dynamics. U73122, a PLC inhibitor, disrupts PLC signaling, indirectly influencing ACAP2 by altering phosphoinositide metabolism, impacting membrane trafficking and vesicle formation.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
SecinH3 | 853625-60-2 | sc-203260 | 5 mg | $278.00 | 6 | |
SecinH3, an ARF inhibitor, disrupts the activation of ARF GTPase. Its influence on ARF signaling indirectly modulates ACAP2 by affecting the ARF-mediated recruitment of ACAP2 to cellular membranes, impacting processes related to membrane trafficking and cellular morphology. | ||||||
2-(Benzoylcarbamothioylamino)-5,5-dimethyl-4,7-dihydrothieno[2,3-c]pyran-3-carboxylic Acid | 314042-01-8 | sc-503400 | 10 mg | $300.00 | ||
CID1067700, a phospholipase D (PLD) inhibitor, disrupts PLD activity. Its action indirectly modulates ACAP2 by altering phospholipid metabolism, impacting ACAP2-associated processes related to membrane trafficking and vesicle formation. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Brefeldin A, a fungal metabolite, inhibits ADP-ribosylation factor (ARF) activation. Its impact on ARF signaling indirectly influences ACAP2 by affecting the ARF-mediated recruitment of ACAP2 to cellular membranes, impacting processes related to membrane trafficking and vesicle formation. | ||||||
Exo1 | 461681-88-9 | sc-200752 sc-200752A | 10 mg 50 mg | $84.00 $297.00 | 4 | |
Exo1, a specific phospholipase D1 (PLD1) inhibitor, disrupts PLD1 activity. Its influence on PLD1 signaling indirectly modulates ACAP2 by altering phospholipid metabolism, impacting ACAP2-associated processes related to membrane trafficking and vesicle formation. | ||||||
Hydroxy-Dynasore | 1256493-34-1 | sc-364678 | 10 mg | $255.00 | ||
Dyngo-4a, a dynamin GTPase inhibitor, disrupts endocytosis. Its action indirectly modulates ACAP2 by affecting dynamin-dependent vesicle trafficking, impacting ACAP2-associated processes related to endocytosis and membrane dynamics. | ||||||
YM201636 | 371942-69-7 | sc-204193 | 5 mg | $217.00 | 6 | |
YM201636, an inhibitor of phosphatidylinositol 4-kinase III beta (PI4KB), disrupts phosphoinositide synthesis. Its influence on PI4KB signaling indirectly modulates ACAP2 by affecting phosphoinositide availability, impacting ACAP2-associated processes related to membrane trafficking and vesicle formation. | ||||||
CAL-101 | 870281-82-6 | sc-364453 | 10 mg | $193.00 | 4 | |
CAL-101 (Idelalisib), a phosphoinositide 3-kinase (PI3K) inhibitor, disrupts PI3K signaling. Its impact on PI3K signaling indirectly influences ACAP2 by altering phosphoinositide availability, impacting ACAP2-associated processes related to membrane trafficking and vesicle formation. | ||||||
EHT 1864 | 754240-09-0 | sc-361175 sc-361175A | 10 mg 50 mg | $213.00 $889.00 | 12 | |
EHT 1864, a Rac1 inhibitor, disrupts Rac1 activation. Its influence on Rac1 signaling indirectly modulates ACAP2 by affecting downstream events, impacting ACAP2-associated processes related to cellular migration and membrane dynamics. | ||||||